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Recombinant factor VIII Fc fusion protein (rFVIIIFc) is a long-acting coagulation factor approved for the
treatment of hemophilia A. Here, the rFVIIIFc manufacturing process and results of studies evaluating
product quality and the capacity of the process to remove potential impurities and viruses are described.
This manufacturing process utilized readily transferable and scalable unit operations and employed
multi-step puriﬁcation and viral clearance processing, including a novel afﬁnity chromatography
adsorbent and a 15 nm pore size virus removal nanoﬁlter. A cell line derived from human embryonic
kidney (HEK) 293H cells was used to produce rFVIIIFc. Validation studies evaluated identity, purity,
activity, and safety. Process-related impurity clearance and viral clearance spiking studies demonstrate
robust and reproducible removal of impurities and viruses, with total viral clearance >8e15 log10 for four
model viruses (xenotropic murine leukemia virus, mice minute virus, reovirus type 3, and suid herpes
virus 1). Terminal galactose-a-1,3-galactose and N-glycolylneuraminic acid, two non-human glycans,
were undetectable in rFVIIIFc. Biochemical and in vitro biological analyses conﬁrmed the purity, activity,
and consistency of rFVIIIFc. In conclusion, this manufacturing process produces a highly pure product
free of viruses, impurities, and non-human glycan structures, with scale capabilities to ensure a
consistent and adequate supply of rFVIIIFc.
© 2015 Biogen. Published by Elsevier Ltd on behalf of The International Alliance for Biological
Standardization. This is an open access article under the CC BY license (http://creativecommons.org/
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.of blood-borne viruses in the 1970s and 1980s related to the use of
plasma-derived clotting factor concentrates [1], the FVIII gene was
cloned and recombinant protein expression and puriﬁcation tech-
niques were developed. While the use of recombinant FVIII (rFVIII)
and improved puriﬁcation methodology contributed to signiﬁcant
improvements in the availability and safety of FVIII replacement
therapy [2], periodic supply shortages and manufacturing quality
breaches have continued into the 2000s. These issues reﬂected the
relative difﬁculty in manufacturing rFVIII, a large, multi-domain
glycoprotein with signiﬁcant post-translational modiﬁcations.
To ensure the safety of rFVIII products, manufacturing processes
should be evaluated for product quality and the capacity to remove
viruses (regulations require demonstration of viral clearance using
3 viruses with differing characteristics and validation of
2 process steps that use different mechanisms for virus inacti-
vation and or/removal) [3,4]. Additionally, processes should aim to
mitigate potential immunogenicity associated with manufacturing
rFVIII products in clonal cell lines [5]. Manufacturing processes for
currently available rFVIII products have previously been described
[6e8]. Recombinant FVIII Fc fusion protein (rFVIIIFc; Biogen,ance for Biological Standardization. This is an open access article under the CC BY
J. McCue et al. / Biologicals 43 (2015) 213e219214Cambridge, MA) is the ﬁrst-approved, long-acting FVIII for adults
and children with hemophilia A for the control and prevention of
bleeding episodes, perioperative management, and routine pro-
phylaxis to prevent or reduce the frequency of bleeding episodes;
it has been designed to reduce the required infusion frequency of
prophylactic treatment [9e12]. The presence of the Fc domain of
human immunoglobulin G1 (IgG1) enables the fusionprotein to bind
to the neonatal Fc receptor (FcRn), part of an endogenous intracel-
lular pathway that delays lysosomal degradation of Fc-containing
proteins (ie, IgG) by cycling them back into circulation [13,14]. Fc
fusion does not signiﬁcantly alter the higher-order structure of FVIII
or its functionality [9,10,15]. The phase 3 A-LONG study demon-
strated an extended half-life of rFVIIIFc relative to rFVIII (~1.5-fold
increase, 19.0 h), as well as the safety and efﬁcacy of rFVIIIFc for
the control and prevention of bleeding episodes [11,12].
The objective of this work was to describe the rFVIIIFc
manufacturing process, and evaluate product quality and the
capacity of this process to produce a product free from viruses and
impurities.
2. Materials and methods
2.1. Manufacturing process: development of the rFVIIIFc cell line,
cell bank, and cell line characterization
The coding sequences for human FVIII and the Fc region of the
human IgG1 (hinge and CH2 and CH3 domains) were obtained by
reverse transcription polymerase chain reaction (RT-PCR) from
human liver polyA mRNA and a human leukocyte cDNA library,
respectively. HEK 293H cells (Invitrogen, Carlsbad, CA) were stably
transfected with an expression vector containing two expression
cassettes. One cassette expressed the native human FVIII signal
sequence followed by a B domain-deleted (BDD) FVIII (S743 to
Q1638 fusion) directly linked to the Fc region of human IgG1 with
no intervening linker. The second expression cassette held Fc with a
heterologous mouse IgkB signal sequence [9,10].
Transfected HEK 293H cells were grown in serum-free medium.
Clonal cell lines were derived and the optimal cell line was selected
based on considerations for rFVIIIFc monomer productivity, rFVIIIFc
activity (measured by chromogenic assay), superior cell growth
properties, and stability. Cell lines with optimal characteristics
were then sub-cloned by limiting dilution and further character-
ized to select the production clonal cell line for manufacturing.
The clonal cell line that was selected for manufacturing was
expanded to create a research cell bank (RCB). The RCB was
expanded to create the master cell bank (MCB) from which a
working cell bank (WCB) was derived. The MCB and WCBs were
tested for identity, purity, and freedom from adventitious agents.
The transgene coding sequence, copy number, and gene integration
patterns of the MCB and a cell bank produced from a cell culture
that was propagated beyond the end of the manufacturing process
were compared based on the International Conference on Harmo-
nisation (ICH) guidelines Q5A, B and D [16e18]. The comparison
was used to assess and conﬁrm transgene integration and stability
of the cell line over the course of the manufacturing process.
To characterize the resultant product from this cell line, rFVIIIFc
was analyzed for the presence of two non-human glycans, terminal
galactose-a-1,3-galactose (a-Gal) and N-glycolylneuraminic acid
(NGNA). a-Gal was released with a-(1-3,4,6) galactosidase, labeled
with 2-aminobenzoic acid, and analyzed with ultra-performance
liquid chromatography (UPLC) with ﬂuorescent detection. NGNA
was released with 50 mM H2SO4, labeled with 1,2 diamino-
4,5-methylenedioxybenzene, and analyzed with UPLC with
ﬂuorescent detection. Three currently available rFVIII products
(Xyntha® [Wyeth Pharmaceuticals Inc, Philadelphia, PA], Advate®[Baxter, Westlake Village, CA], and Kogenate® [Bayer, Tarrytown,
NY]) were also analyzed for the presence of a-Gal and NGNA using
the same analytical methods.2.2. Production of rFVIIIFc
One WCB vial was used to produce a single batch of rFVIIIFc in a
multi-step manufacturing process (Fig. 1). The inoculum preparation
phase includes thawing aWCB vial (Step 0) and expansion of culture
in shake ﬂasks (Step 1). Shake ﬂasks were then pooled and used to
inoculate theﬁrst seed trainbioreactor (for further culture expansion;
Step 2). The seed train bioreactorswere operated in batchmode,with
agitation, pressure, temperature, pH, and dissolved oxygen
controlled. The expanded culture was used to inoculate a large-scale
production bioreactor (Step 3). The production bioreactor (2000 L)
was operated in fed-batch mode, during which agitation, pressure,
temperature, pH, and dissolved oxygenwere controlled.
Cells and cellular debris were removed by centrifugation (Step 4)
and subsequent depth ﬁltration steps (Step 5) to produce a clariﬁed
cell culture harvest containing the rFVIIIFc product. Detergent (Triton
X-100; Step 6) was added to the clariﬁed cell culture harvest as a
virus inactivation step. The product was then captured and puriﬁed
from the clariﬁed cell culture harvest with a FVIII-speciﬁc afﬁnity
chromatography step using an VIIISelect column (GE Healthcare Life
Sciences, Piscataway, NJ; Step 7). VIIISelect is an immobilized re-
combinant peptide-based afﬁnity ligand speciﬁc for FVIII that is both
highly effective and free of animal components, such as mouse
monoclonal antibodies [19]. The VIIISelect adsorbent binds to the
FVIII light chain portion of rFVIIIFc, and the product is desorbed and
collected using a buffer solution at neutral pH, to ensure the integrity
of rFVIIIFc is maintained. rFVIIIFc was further puriﬁed by charge-
based separation using anion exchange chromatography (Step 8)
followed by a ﬂow-through anion-exchange membrane absorber
(Step 9). The rFVIIIFc product was then ﬁltered through a 15 nmvirus
ﬁlter (Planova™ 15N; Asahi Kasei Bioprocesses, Inc., Glenview, IL;
Step 10) to purify based on size. The virus-ﬁltered product was
further puriﬁed using a ﬁnal chromatography step (Hydrophobic
Interaction Chromatography [HIC]; Step 11). rFVIIIFc was concen-
trated and buffer-exchanged using an ultraﬁltration step (Step 12) to
form the bulk product. The bulk product was formulated and ﬁltered
into bottles (Step 13) and stored at70 C to ensure stability prior to
lyophilization and before ﬁnal ﬁlling into individual drug product
vials for use in clinical study.2.3. Manufacturing process and impurity clearance validation
studies
Process validation studies were performed to conﬁrm identity,
purity, quality, and activity of the rFVIIIFc product. A summary of
the analytical tests used in these assessments is shown in Table 1.
Non-reducing sodium dodecyl sulfate polyacrylamide gel electro-
phoresis (SDS-PAGE) gels stained with colloidal Coomassie blue,
thrombin digest map, FVIII chromogenic assay and size exclusion
chromatography were also employed in validation studies for pu-
rity assessment and identity conﬁrmation. The presence of aggre-
gated species (proteins that have undergone conformational
changes during the manufacturing or storage processes resulting in
misfolded protein species), was determined using size exclusion
chromatography (SEC) [20]. Fc-binding activity was determined
using an FcRn binding assay [21]. The speciﬁc activity of rFVIIIFc
was assessed using both the two-stage chromogenic substrate and
one-stage activated partial thromboplastin time (aPTT) clotting
assays [9]. Safety determination was based on testing for the
presence of bioburden and endotoxin.
Fig. 1. Overview of the rFVIIIFc manufacturing process. aViral clearance steps.
J. McCue et al. / Biologicals 43 (2015) 213e219 215The puriﬁcation process was designed to provide a high level of
viral clearance for potential adventitious viruses. To demonstrate
the capacity and robustness of the manufacturing process (and
individual steps) to remove adventitious viruses, the puriﬁcationTable 1
Analytical tests used to assess identity, purity, activity, and safety of rFVIIIFc.
Test Method description
Polyacrylamide gel
electrophoresis
(non-reducing)
Polyacrylamide gel electrophoresis performed in the
presence of sodium dodecyl sulfate (SDS-PAGE) under
non-reducing conditions. Gels are stained using
Colloidal Coomassie Blue staining
Size exclusion
chromatography
Resolution of aggregated forms from the monomeric
form of rFVIIIFc using high performance liquid
chromatography (Sepax SRT SEC-300 column)
Coagulation activity One-stage activated partial thromboplastin time (aPTT)
clotting assay method performed in accordance with
Pharmacopeia guidelines (USP<32> and Ph. Eur. 2.7.11)
Chromogenic activity Colorimetric method performed in accordance with
Pharmacopeia guidelines (Ph. Eur. 2.7.4)
FcRn binding Neonatal Fc receptor (FcRn) competitive binding
measured using an ampliﬁed luminescent proximity
homogenous assay
Bioburden Microbial enumeration test performed in accordance
with Pharmacopeia guidelines (USP<61> and Ph. Eur.
2.6.12)
Endotoxin Kinetic turbidimetric method in accordance with
Pharmacopeia guidelines (USP<85> and Ph. Eur. 2.6.14)
FcRn, neonatal Fc receptor; Ph. Eur., European Pharmacopeia; SDS-PAGE, sodium
dodecyl sulfate polyacrylamide gel electrophoresis.process was evaluated for the capacity for removal of enveloped
and non-enveloped viruses using four model viruses (xenotropic
murine leukemia virus [X-MLV], mouse minute virus [MMV],
mammalian orthoreovirus 3 [Reo-3; also known as reovirus
serotype 3], and suid herpes virus 1 [SuHV-1; also known as
pseudorabies virus]; Table 2). These viruses were selected to
represent ranges of physiochemical properties of several human
virus families, such as retroviruses, herpes viruses, reoviruses,
and parvovirus. These studieswere conducted according to the ICH
Q5A Guidelines and the US Food and Drug Administration Points
to Consider [16,22] and in accordance with Good Laboratory
Practice [23].
The rFVIIIFc manufacturing process was also evaluated for the
capacity to remove process-related impurities. Process-related
impurity clearance validation studies were performed both at the
manufacturing scale and in scaled-down spiking studies at the
laboratory scale. Those performed at the manufacturing scale
consisted of direct measurement of the impurities obtained from
the manufacturing process intermediates, in which clearance was
calculated from the amount removed during the process step.
Scaled-down impurity clearance validation studies involved adding
an impurity to the process intermediate and purifying the spiked
intermediate using a scaled-down chromatography step. These
studies were used when the impurity was below detectable levels
in the manufacturing process intermediates and to demonstrate
the capacity and robustness of the process to provide additional
clearance.
Table 2
Summary of rFVIIIFc viral clearance validation studies and virus clearance reduction factors.
Virus name Virus type Virus size
(nm)
Virus reduction factor (LRV)
Detergent
inactivation
(log10)
Afﬁnity
chromatography
(log10)
Anion exchange
chromatography
(log10)
Viral ﬁltration
(Planova 15N)
(log10)
Total clearance
(log10)a
Xenotropic murine leukemia
virus (X-MLV)
Retrovirus 80e130 4.4b 2.4 2.7 5.6b 15.1
Suid herpes virus 1 (SuHV-1) Enveloped DNA
virus
120e200 4.4b 3.1 NP 4.0b 11.5
Reovirus type 3 (Reo-3) Non-enveloped
RNA virus
60e80 NP 2.8 NP 5.5b 8.3
Mouse minute virus (MMV) Small DNA virus 18e22 NP >4.6b 1.6 5.7b 11.9
NP, not performed; log10, log reduction value of viral clearance.
The LRV of four viruses for the rFVIIIFc puriﬁcation process steps are included.
a Total clearance (LRV) represents the summation of the steps evaluated for viral clearance for the four viruses evaluated in the studies.
b The “>” indicates virus levels were below levels of detection for the respective step.
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3.1. Cell line safety and characterization
The MCB and WCB were manufactured in accordance with
current Good Manufacturing Practice procedures, with purity,
safety, and identity test results demonstrating no detectable virus
or adventitious agents. Testing with random ampliﬁed poly-
morphic DNA, isoenzyme analysis, and RT-PCR conﬁrmed the cell
bank origin; microbial and viral testing conﬁrmed they were free of
bacteria, fungi, mycoplasma, and adventitious viruses. Additionally,
the cell line chosen resulted in a product free of the non-human
glycans, terminal a-Gal and NGNA (Table 3).3.2. Validation studies: assessment of product quality and process
consistency
The rFVIIIFc manufacturing process generated product of
consistent purity, quality, and activity. All manufacturing steps
were successfully validated for consistency based on process per-
formance and product quality data from four batches. The
manufacturing process validation study demonstrated consistency
through evaluation of controlled parameters, in-process controls,
and product quality. Results from four validation batches are shown
in Table 4. All batches demonstrated >97% purity, when measured
by non-reducing SEC and SDS-PAGE (Fig. 2).Table 3
Levels of A) galactose-a-1,3-galactose (a-Gal) and B) N-glycolylneuraminic acid
(NGNA) in rFVIIIFc and three commercially available rFVIII products.
Sample a-Gal NGNA
Average %
mol/mol
(n ¼ 3)
Standard
deviation
(n ¼ 3; %)
Average
% mol/mol
(inter-day;
n ¼ 9)a
RSDb
(inter-day;
n ¼ 9; %)a
rFVIIIFc <LODc NA <LODd NA
Xyntha 10.2 1.6 20.31 (0.73) 3.6
Advate 3.3 0.6 1.33 (0.14) 10.8
Kogenate 1.3e 0.8 5.99 (0.32) 5.3
Positive control 41.7 0.4 e e
a-Gal, galactose-a-1,3-galactose; LOD, limit of detection; NA, not applicable; NGNA,
N-glycolylneuraminic acid; rFVIIIFc, recombinant factor VIII Fc fusion protein; rFVIII,
recombinant factor VIII; RSD, relative standard deviation.
a Analysis was done in triplicate on 3 separate days (total of n ¼ 9).
b Inter-day (n ¼ 3 days) RSD.
c LOD is 1.1% (0.1 pmol) for rFVIIIFc.
d LOD is 0.28% (2.5 fmol) for rFVIIIFc.
e 1.3% is at the LOD (1.3% [0.1 pmol]) but below the limit of quantiﬁcation
(2.6% [0.2 pmol]).Table 4 also shows that the speciﬁc activity of rFVIIIFc was
consistent among the validation batches, with batches possessing
speciﬁc activity values of 1660e1770 IU/nmol of rFVIIIFc for the
aPTT assay and values of 1420e1720 IU/nmol for the chromogenic
substrate assay. Importantly, comparable ranges for speciﬁc activity
were achieved using both the aPTT and chromogenic substrate
assays. Additionally, results were comparable to the speciﬁc activity
of native FVIII (1429 IU/nmol) [10] and speciﬁc activities previously
reported for rFVIIIFc (1861 ± 154 IU/nmol and 2057 ± 298 IU/nmol
using the one-stage aPTT and chromogenic substrate assays,
respectively) and that reported for ReFacto® (1862 IU/nmol) [9]. In
addition, potency of rFVIIIFc in binding to FcRn was consistent
across the batches. No bioburden was detected in any of the
batches, and endotoxin levels were all below detectable levels.
Overall, results from analytical testing demonstrated that the
manufacturing process consistently produced a highly pure and
active rFVIIIFc product.3.3. Validation studies: virus- and process-related impurity
clearance
Virus removal studies demonstrated signiﬁcant clearance of
viruses possessing different physical and chemical properties. The
overall total clearance for the rFVIIIFc puriﬁcation process was
15.1 log10 for X-MLV,11.5 log10 for SuHV-1,8.3 log10 for MRV-3,
and 11.9 log10 for MMV. The detergent virus inactivation step,
the VIIISelect afﬁnity chromatography step, the anion exchange
chromatography step, and the virus ﬁltration step (Planova 15N)
each contributed to this viral clearance, with the most substantial
removal of model virus achieved with the use of the 15N Planova
nanoﬁlter (Table 2).
In addition to providing robust removal of viruses, the rFVIIIFc
puriﬁcation process also provided robust and reproducible
clearance of process-related impurities. Reductions in HEK 293H
host cell proteins (HCP), HEK 293H host cell DNA, and Triton X-100
are shown in Table 5. Levels of VIIISelect ligand leachate were
below detectable levels during the manufacturing process and in
the ﬁnal product, demonstrating that only minimal, sub-detectable
levels may leach during the manufacturing process. A reduction
factor of 0.8 log10, obtained by performing scale-down spiking
studies of the VIIISelect ligand, further illustrates the robustness of
the rFVIIIFc manufacturing process to remove any residual
VIIISelect ligand that may be present following the VIIISelect
chromatography step. Additionally, levels of host cell DNA were
below detectable levels (<1 pg DNA/mg rFVIIIFc) in the ﬁnal
product, well below the level that is considered acceptable by the
World Health Organization [24].
Fig. 2. A) Structural components of rFVIIIFc: the single-chain (SC) non-processed isoform and the processed isoform (FVIII light chain [A3, C1, C2] covalently linked to Fc dimer
[LCeFc/Fc]); B) Non-reducing SDS-PAGE analysis of rFVIIIFc validation batch (RECD19189-11-011) used for the determination of purity and identity. The three bands are indicative of
the three components of rFVIIIFc: FVIII heavy chain (HC), the processed isoform, and the SC isoform. Non-reducing SDS-PAGE was conducted on a 4%e12% polyacrylamide gel in
BiseTris buffer. Samples were denatured with SDS in the presence of 15 mM N-ethylmaleimide for 5 min at 75 C. The gel was stained with Colloidal Coomassie. SDS-PAGE, sodium
dodecyl sulfate polyacrylamide gel electrophoresis; MW, molecular weight; HC, FVIII heavy chain; LCeFc/Fc, FVIII light chain covalently linked to Fc dimer; SC, single-chain.
Table 4
Product quality results from four validation batches.
Product attribute Test method Results
11-011 11-012 11-013 11-014
Identity Non-reducing SDS-PAGE; Comparable to reference standard
Thrombin digest map Conforms to reference standard
FVIII chromogenic substrate assay Meets biologic activity speciﬁcation
Purity Non-reducing gel electrophoresis (%) 97.7 98.1 98.2 98.6
Size exclusion chromatography (%) >99.0 >99.0 >99.0 >99.0
Activity Coagulation activity based on one-stage
aPTT clotting assay speciﬁc activity
(IU/nmol rFVIIIFc)a
1660 1700 1770 1660
Activity based on chromogenic substrate
assay speciﬁc activity (IU/nmol rFVIIIFc)a
1420 1620 1640 1720
FcRn binding relative potencyb (%) 127 127 120 122
Safety Bioburden (CFU/10 mL) 0 0 0 0
Endotoxin (EU/mL) <1.00 <1.00 <1.00 <1.00
aPTT, activated partial thromboplastin time; CFU, colony-forming units; ELISA, enzyme-linked immunosorbent assay; EU, endotoxin units; FcRn, neonatal Fc receptor; rFVIIIFc,
recombinant factor VIII Fc; SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis; WHO, World Health Organization.
a Coagulation activity is calibrated against the WHO international standard for FVIII. For comparison, the speciﬁc activity of rFVIII is 1429e1862 [9,10].
b One GMP batch manufactured using the same process, scale, and facility has been designated as a reference standard. Potency was determined against this reference
standard.
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Many technologic advances have offered beneﬁts to the
hemophilia A population since FVIII was found to be enriched in the
cryoprecipitate of fresh frozen plasma in 1964 [25]. This discovery
led to the development of plasma-derived factor replacement
therapies. However, there was widespread contamination of theseTable 5
Summary of impurity clearance achieved throughout the rFVIIIFc manufacturing
process for select process-related impurities.
Process-related impurity Impurity clearance
validation scale
Overall reduction
factor (log10)a,b
HEK 293H HCP Manufacturing 5.6
HEK 293H DNA Manufacturing >7.0
VIIISelect Ligand
Leachate
Laboratory 0.8
Triton X-100 Laboratory >8.9
HCP, host cell protein; HEK, human embryonic kidney; rFVIIIFc, recombinant factor
VIII Fc.
a Overall reduction factor (log10) is the sum of the reduction factor values for each
of the process steps validated for removal of the respective process-related
impurities.
b Reduction factor ¼ log10 (impurity load of input/impurity load of output).products with hepatitis and HIV in the 1970s and 1980s [1]. Viral
safety concerns accelerated the development of recombinant
clotting factors (initial approval in 1992). However, plasma proteins
added to stabilize the ﬁnal formulation of ﬁrst generation products
(eg, albumin) and plasma-derived proteins used in the cell culture
medium of second generation products continued to fuel concerns
about viral transmission (additionally, supply shortages occurred
through the early 2000s). The advent of third generation products,
free of human and animal proteins, has ushered in a new era of
theoretical safety; however, despite high theoretical safety, the
hemophilia community has remained concerned about viral
transmission. This illustrates the key importance of conducting
manufacturing validation studies in recombinant products that
demonstrate viral clearance and removal of other impurities.
The rFVIIIFc manufacturing process validation studies described
herein demonstrated the capacity of the manufacturing process to
produce a product of consistent high quality and purity and to
remove potential viruses and process-related impurities. This
process uses a number of recently developed techniques to ensure
product quality and purity, including a virus inactivation step, three
different chromatography steps, and a 15 nm pore size virus ﬁlter to
provide robust removal of viruses.
J. McCue et al. / Biologicals 43 (2015) 213e219218A key feature of rFVIIIFc's manufacturing process is the use of a
human cell line and a process that is free from added human-
or animal-derived components. The HEK 293H cell line has
biochemical properties that are advantageous for recombinant
protein expression, such as amenability to transfection, high
efﬁciency, and effective translation of human protein processing
and production [26e28]. This cell line has been selected to produce
a number of human recombinant protein therapeutics, including
drotrecogin alfa-activated protein C, a factor VIII product, and a
factor IX product [5,27e31]. Another advantage of using a human
cell line is this ensures no non-human glycan structures are
incorporated into the expressed proteins, which need to be moni-
tored and screened for during cell line development in cells lines
derived from rodents [32,33]. Results of this work indicate that the
use of a human cell line to manufacture rFVIIIFc yields a product
free of the non-human glycan structures found in proteins
expressed in hamster cell lines. It has been previously reported that
all humans possess anti-NGNA antibodies and sometimes at high
levels, approaching 0.1%e0.2% of circulating IgG [34]. Anti-a-Gal
antibodies (IgE) have also been previously observed in humans
[35]. As a result, a-Gal and NGNA are potentially immunogenic. In
this analysis, neither NGNA nor a-Gal were detected in rFVIIIFc, but
different amounts of both were found in the three commercially
available rFVIII products: Advate, Xyntha, and Kogenate (Table 3),
all produced with hamster cell lines. Although the impact of these
antigens in vivo is not known, their absence may result in lower
immunogenicity [5].
Similar viral clearance steps that include multiple chromatog-
raphy steps, a virus ﬁltration step, and a virus inactivation step have
also been utilized to manufacture other rFVIII products. To our
knowledge, this is the ﬁrst reported use of a 15 nm nanoﬁlter in the
manufacturing process of a rFVIII product. The viral clearance
resulting from the manufacturing process of rFVIIIFc can be
compared with that of another rFVIII product produced in
mammalian (CHO) cells [6]. The CHO-based rFVIII process achieved
>11.4 logs for X-MLV, >14.0 logs for SuHV-1, >10.3 logs for Reo-3,
and 5.2 logs for MMV. The process removed viruses to below
detectable levels for three of the four model viruses evaluated in
the studies (X-MLV, SuHV-1, and Reo-3). However, the process did
not clear MMV to below detectable levels, achieving an overall
clearance of 5.2 logs compared with >11.9 logs achieved using the
rFVIIIFc manufacturing process. This may be due to the use of a
larger (35 nm) pore size virus ﬁlter in the rFVIII manufacturing
process, which was less effective at removing relatively small MMV
viruses. MMV is a surrogate for parvoviruses, among the smallest
human pathogens.
Reducing the pore size in nanoﬁltration is known to greatly
enhance the effectiveness of viral clearance without affecting
puriﬁed FVIII [36]; the small pore size (15 nm) of the Planova 15N
virus ﬁlter provides an effective barrier for a wide range of large-
size impurities. In the current study, the Planova 15N ﬁlter pro-
vided an extremely stringent level of clearance providing a total
reduction factor8.3 log10 for each of the model viruses tested and
>15 log10 clearance of retroviruses. Overall, these results demon-
strate that the rFVIIIFc manufacturing process can effectively clear
retroviruses, in addition to a broad spectrum of adventitious virus
types.
5. Conclusions
Over more than two decades, the safety of manufactured rFVIII
proteins has improved dramatically compared with the previous
manufacture of plasma-derived FVIII, but has not been without
challenges. The rFVIIIFc manufacturing process employs multiple
new methods including a unique cell line and state-of-the-artpuriﬁcation and viral ﬁltration to consistently produce a novel, fully
active, and highly puriﬁed product free from viral contaminants or
impurities. Importantly, by utilizing a scalable and transferable
process, the product can be produced within any of the manufac-
turer's large-scale manufacturing facilities, reducing supply risks
[37].
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